LIMINATUS PHARMA, INC. Payments to Acquire Loans Receivable
LIMINATUS PHARMA, INC. (LIMN) reported Payments to Acquire Loans Receivable of $775.00 thousand for the 12-month period ending 2025-12-31, per its S-1 filed 2026-06-24.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireLoansReceivable · last filed 2026-08-14
- LIMINATUS PHARMA, INC. payments to acquire loans receivable for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- LIMINATUS PHARMA, INC. payments to acquire loans receivable for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- LIMINATUS PHARMA, INC. payments to acquire loans receivable for the quarter ending 2025-06-30 was $200.00K.
- LIMINATUS PHARMA, INC. payments to acquire loans receivable for the quarter ending 2025-03-31 was $575.00K.
| Period end | Payments to Acquire Loans Receivable 3 month | Payments to Acquire Loans Receivable 6 month | Payments to Acquire Loans Receivable 9 month | Payments to Acquire Loans Receivable 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: S-1 12 month − 10-Q 9 month · filed 2026-06-24 | $0.00 derived: sum of 2 quarters · filed 2026-06-24 | $200.00K derived: sum of 3 quarters · filed 2026-08-14 | $775.00K S-1 · filed 2026-06-24 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $200.00K derived: sum of 2 quarters · filed 2026-08-14 | $775.00K 10-Q · filed 2025-11-14 | $1.32M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $200.00K derived: 10-Q 6 month − S-1 3 month · filed 2026-08-14 | $775.00K 10-Q · filed 2026-08-14 | $1.32M derived: sum of 3 quarters · filed 2026-08-14 | $2.13M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $575.00K S-1 · filed 2026-06-24 | $1.13M derived: sum of 2 quarters · filed 2026-06-24 | $1.93M derived: sum of 3 quarters · filed 2026-06-24 | |
| 2024-12-31 | $550.00K derived: S-1 12 month − 10-Q 9 month · filed 2026-06-24 | $1.35M derived: sum of 2 quarters · filed 2026-06-24 | $2.85M S-1 · filed 2026-06-24 | |
| 2024-09-30 | $800.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $2.30M 10-Q · filed 2025-11-14 | ||
| 2024-06-30 | $1.50M 10-Q · filed 2025-10-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |